Lin Shen

26.8k total citations · 5 hit papers
487 papers, 15.4k citations indexed

About

Lin Shen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Lin Shen has authored 487 papers receiving a total of 15.4k indexed citations (citations by other indexed papers that have themselves been cited), including 308 papers in Oncology, 207 papers in Pulmonary and Respiratory Medicine and 142 papers in Surgery. Recurrent topics in Lin Shen's work include Gastric Cancer Management and Outcomes (139 papers), Colorectal Cancer Treatments and Studies (104 papers) and Cancer Immunotherapy and Biomarkers (85 papers). Lin Shen is often cited by papers focused on Gastric Cancer Management and Outcomes (139 papers), Colorectal Cancer Treatments and Studies (104 papers) and Cancer Immunotherapy and Biomarkers (85 papers). Lin Shen collaborates with scholars based in China, United States and Japan. Lin Shen's co-authors include Yoon‐Koo Kang, Atsushi Ohtsu, Hyun Cheol Chung, Yung‐Jue Bang, Eric Van Cutsem, Akira Sawaki, Е. С. Куликов, A. Feyereislova, Taroh Satoh and Florian Lordick and has published in prestigious journals such as Science, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Lin Shen

455 papers receiving 15.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

2010 5.3k citations Hyun Cheol Chung, Lin Shen et al. profile →
Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells

2020 940 citations Lin Shen et al. profile →
Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study

2013 379 citations Jaffer A. Ajani, Hyun Cheol Chung et al. profile →
Fifteen-Year Effects of Helicobacter pylori, Garlic, and Vitamin Treatments on Gastric Cancer Incidence and Mortality

2012 344 citations Lin Shen et al. profile →
Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study

2018 336 citations Lin Shen, Manish A. Shah et al. profile →

Peers

Countries citing papers authored by Lin Shen

Since Specialization

Citations

This map shows the geographic impact of Lin Shen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lin Shen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lin Shen more than expected).

Fields of papers citing papers by Lin Shen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lin Shen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lin Shen. The network helps show where Lin Shen may publish in the future.

Co-authorship network of co-authors of Lin Shen

This figure shows the co-authorship network connecting the top 25 collaborators of Lin Shen. A scholar is included among the top collaborators of Lin Shen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lin Shen. Lin Shen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical and splenectomy-based treatment outcomes in 40 cases of hepatosplenic T-cell lymphoma: a comprehensive analysis 2024 ·World Journal of Surgical Oncology ·(unknown), Min Wu, (unknown), Lin Shen	0
2	132MO Anti-claudin18.2 (CLDN18.2) antibody-drug conjugate (ADC) IBI343 in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC): Updated results from a phase I study 2024 ·Annals of Oncology ·Xianjun Yu, Xiaofeng Zhang, J. J. Liu, Jianwei Yang, Jinbo Yue, Yuping Sun, Ying Pan, Meili Sun, Yanru Qin, Lin Shen, (unknown), Jian Ruan, Aiping Zhou, Yi Mou, Morteza Aghmesheh, M. D. Morris, Xiaokun Zhao, Ming Chen, Andrea Tazbirkova	2
3	LINC00618 facilitates growth and metastasis of hepatocellular carcinoma via elevating cholesterol synthesis by promoting NSUN2-mediated SREBP2 m5C modification 2024 ·Ecotoxicology and Environmental Safety ·Li Rong, Shunle Li, Lin Shen, Junhui Li, Di Zhang, (unknown), (unknown), Na Liu, Hongwei Lü, (unknown)	10
4	B7-H3–Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors 2024 ·Cancer Research ·Licui Jiang, Fengtao You, (unknown), Changsong Qi, (unknown), (unknown), Huimin Meng, (unknown), (unknown), (unknown), (unknown), Gangli An, (unknown), Bozhen Zhang, Lin Shen, Lin Yang	7
5	Quinoline-based anti-MRSA agents: Current development, structure-activity relationships, and mechanisms 2023 ·Chinese Chemical Letters ·Hong Yao, (unknown), Hang Liu, (unknown), Lin Shen, Ruige Yang, Shangshang Qin, Yong Guo	9
6	Phase I study of MSB2311, a novel pH-dependent anti-PD-L1 monoclonal antibody, treating patients with advanced solid tumors and lymphoma 2023 ·Cancer Immunology Immunotherapy ·Qi Zhang, Jian Zhang, Haijun Zhong, Ying Yuan, Lei Yang, Qingyuan Zhang, Dongmei Ji, Jifang Gong, Jing Li, Zhenling Yao, (unknown), Jianming Wang, Л. Лу, Michael Shi, (unknown), Lin Shen, Jian Li, Xichun Hu	1
7	Maintenance regimen of GM‐CSF with rituximab and lenalidomide improves survival in high‐risk B‐cell lymphoma by modulating natural killer cells 2023 ·Cancer Medicine ·(unknown), (unknown), Lin Shen, Min Wu, (unknown), (unknown), Pingping Chen, Yingwei Hu, Mingyue Chen, Yu Xu, Hong‐Di Zhang, Jiexian Ma, Yanhui Xie	3
8	1018O Phase I study of GCC CAR-T therapy IM96 in patients with advanced colorectal cancer 2023 ·Annals of Oncology ·Changsong Qi, Liangzheng Chang, Jiyao Li, (unknown), Xianding Wang, Zemin Wang, Xiong Lu, Tianyou He, Yan Ding, (unknown), Donghui Liu, Lin Shen	2
9	Real‐world treatment and outcomes of patients with metastatic BRAF mutant colorectal cancer 2023 ·Cancer Medicine ·Ting Xu, Jian Li, Zhenghang Wang, Xiaotian Zhang, Jun Zhou, Zhihao Lü, Lin Shen, Xicheng Wang	9
10	134MO Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab + CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma 2023 ·Annals of Oncology ·Florian Lordick, Manish A. Shah, Kohei Shitara, Jaffer A. Ajani, Y-J. Bang, Peter C. Enzinger, David H. Ilson, (unknown), Javier Gállego, Jee‐Fu Huang, Lin Shen, Sang Cheul Oh, Patrapim Sunpaweravong, (unknown), Hacı Mehmet Türk, J.W. Park, Diarmuid Moran, P. Bhattacharya, Yue Cao, (unknown)	2
11	1524P First-line TST001 plus capecitabine and oxaliplatin (CAPOX) for advanced G/GEJ cancer with CLDN18.2 positive overall survival data from study transtar102-Cohort C 2023 ·Annals of Oncology ·Lin Shen, (unknown), Ningning Li, Weijian Guo, Tianshu Liu, Li Zhang, Xia Zhu, Chong Qi, Li Xu, Xiaoping Qian, Caroline Germa	3
12	P-138 Margetuximab combined with anti-PD-1 (retifanlimab) or anti-PD-1/LAG-3 (tebotelimab) +/- chemotherapy in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction or gastric cancer 2021 ·Annals of Oncology ·Daniel V.T. Catenacci, Minori Koshiji Rosales, Hyun Cheol Chung, Harry H. Yoon, Markus Moehler, Yoon‐Koo Kang, Lin Shen	1
13	The Gut Microbiome Is Associated with Clinical Response to Anti–PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer 2020 ·Cancer Immunology Research ·Zhi Peng, Siyuan Cheng, Yan Kou, Ziqi Wang, Rong Jin, Hu Han, Xiaotian Zhang, Jifang Gong, Jian Li, Ming Lu, Xicheng Wang, Jun Zhou, Zhihao Lü, Quan Zhang, David T.W. Tzeng, (unknown), Yan Tan, Lin Shen	235
14	Favorable response to immunotherapy in a pancreatic neuroendocrine tumor with temozolomide‐induced high tumor mutational burden 2020 ·Cancer Communications ·Yanshuo Cao, Yutong Ma, Jiangyuan Yu, Yu Sun, Tingting Sun, Yang Shao, Jie Li, Lin Shen, Ming Lu	19
15	Evolutionary Expression of HER2 Conferred by Chromosome Aneuploidy on Circulating Gastric Cancer Cells Contributes to Developing Targeted and Chemotherapeutic Resistance 2018 ·Clinical Cancer Research ·Yilin Li, Xiaotian Zhang, Dan Liu, Jifang Gong, Daisy Dandan Wang, Shan Li, Zhi Peng, Yanyan Li, Xiaojuan Wang, Peter Ping Lin, Min Li, Lin Shen	46
16	The Empirical Study of the Education Investment’s Influences on the Industrial Structure Rationalization in Hainan Province 2017 ·Journal of Service Science and Management ·Dan Yu, Shasha Gao, Lin Shen	2
17	Benefit of percutaneous endoscopic gastrostomy in patients undergoing definitive chemoradiotherapy for locally advanced nasopharyngeal carcinoma 2016 ·SHILAP Revista de lepidopterología ·(unknown), Guo Q, Jing Lin, (unknown), (unknown), Theresa T. Lu, (unknown), (unknown), Jinhua Pan, Lin Shen	0
18	Tumor MET Expression and Gene Amplification in Chinese Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer 2015 ·Molecular Cancer Therapeutics ·Zhi Peng, Zhongwu Li, Jing Gao, Ming Lu, Jifang Gong, En‐Tzu Tang, Kelly S. Oliner, Yong-Jiang Hei, Hui Zhou, Lin Shen	19
19	A Multicenter Feasibility Study with S-1, Oxaliplatin and Oral Leucovorin (SOL) for the Patients with Untreated Metastatic Colorectal Cancer: The Result of Final Analysis. 2014 ·PubMed ·Ming Lü, Yan Wang, Wei Liu, Chunmei Bai, Jianming Xu, Lin Shen	1
20	[Trastuzumab combined with chemotherapy in patients with HER2-positive chemo-refractory advanced gastric or gastro-esophageal junction adenocarcinoma]. 2014 ·PubMed ·Xiaotian Zhang, (unknown), Jifang Gong, (unknown), (unknown), Xicheng Wang, Ming Lü, Jian Li, Yanshuo Cao, Yan Li, Jie Li, Lin Shen	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact